Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE HYDROCHLORIDE AND IBUPROFEN vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full mu-opioid receptor agonist, leading to analgesia, euphoria, and sedation. Ibuprofen inhibits cyclooxygenase (COX)-1 and COX-2, reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate,Off-label: Treatment of chronic pain when other options fail
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
One tablet containing oxycodone hydrochloride 5 mg and ibuprofen 400 mg orally every 6 hours as needed for pain; maximum 4 tablets per day.
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Oxycodone: 3-5 hours; Ibuprofen: 1.8-2.5 hours. Clinical context: Oxycodone's half-life allows dosing every 4-6 hours; Ibuprofen's shorter half-life supports frequent dosing for sustained anti-inflammatory effect.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Oxycodone is metabolized primarily via CYP3A4 and CYP2D6 to active metabolites (noroxycodone, oxymorphone). Ibuprofen is metabolized via CYP2C9 and CYP2C8 to inactive metabolites.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Oxycodone: primarily renal (87%) as metabolites, with ~19% unchanged; Ibuprofen: renal (90%) as metabolites, with ~10% unchanged; small biliary/fecal elimination for both.
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Oxycodone: ~45% bound to albumin; Ibuprofen: >99% bound to albumin.
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Oxycodone: Vd 2.0-3.0 L/kg (high tissue distribution: CNS, muscle); Ibuprofen: Vd 0.1-0.2 L/kg (limited to plasma and extracellular fluid).
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Oral: Oxycodone 60-87% (higher with repeated dosing due to saturation of first-pass); Ibuprofen 80-100% (rapidly absorbed).
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
GFR 30-89 m L/min: No adjustment recommended. GFR 15-29 m L/min: Use with caution; consider reducing dose or extending interval; avoid use in severe renal impairment (GFR <30 m L/min) due to risk of ibuprofen accumulation and nephrotoxicity. GFR <15 m L/min: Not recommended.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
Child-Pugh Class A (mild): No adjustment recommended. Child-Pugh Class B (moderate): Use with caution; reduce starting dose of oxycodone by 50% (e.g., half tablet) and monitor; ibuprofen should be avoided or used at lowest effective dose. Child-Pugh Class C (severe): Contraindicated due to risk of hepatic encephalopathy and bleeding.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Not approved in children <18 years of age. For weight-based dosing in adolescents (≥18 years): same as adult based on oxycodone component 0.05-0.15 mg/kg/dose (max 5 mg) and ibuprofen 5-10 mg/kg/dose (max 400 mg) every 6 hours as needed; not to exceed 4 doses per day.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Start at lowest effective dose (one-half tablet every 6 hours) due to increased sensitivity to opioids (respiratory depression, constipation) and NSAID-related GI/renal risks; monitor renal function and for cognitive impairment; maximum 4 tablets per day.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of just one dose, especially by children, can be fatal; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to ibuprofen.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Respiratory depression; addiction potential; interactions with CNS depressants; hepatic impairment; renal toxicity; gastrointestinal bleeding; cardiovascular thrombotic events; adrenal insufficiency; use in elderly; use in pregnancy; breastfeeding.
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; hypersensitivity to oxycodone, ibuprofen, or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery.
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Take with food or milk to reduce GI upset. Avoid grapefruit and grapefruit juice (may increase oxycodone levels and risk of adverse effects). Limit alcohol intake due to additive CNS depression and increased GI bleeding risk.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
First trimester: Limited data; opioid use associated with neural tube defects and congenital heart defects in some studies; ibuprofen associated with increased risk of cardiac defects and gastroschisis. Second trimester: Ibuprofen may cause oligohydramnios and premature closure of fetal ductus arteriosus. Third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome; ibuprofen contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal nephrotoxicity.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Oxycodone excreted in breast milk; M/P ratio approximately 1.1. Ibuprofen excreted in low levels (M/P <0.01). American Academy of Pediatrics considers both compatible with breastfeeding; however, monitor infant for sedation, respiratory depression, and poor feeding due to oxycodone.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
No established dose adjustments for pregnancy; however, increased renal clearance and volume of distribution in pregnancy may require dose increases for adequate analgesia. Avoid supratherapeutic ibuprofen doses; limit to lowest effective dose and shortest duration. Third trimester: avoid ibuprofen entirely.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
Combination product (oxycodone 5 mg/ibuprofen 400 mg) indicated for acute moderate-to-severe pain; limit duration to ≤7 days due to opioid dependence and GI/renal risks; avoid in patients with aspirin/NSAID allergy, asthma, or severe hepatic/renal impairment; monitor for respiratory depression, hypotension, and signs of bleeding; prescribe naloxone for high-risk patients.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not drive or operate machinery until you know how this medication affects you.,This drug contains both an opioid and an NSAID; risk of addiction, respiratory depression, and GI bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or acetaminophen-containing products without medical advice.,Swallow tablets whole; do not crush, chew, or dissolve (may cause rapid release and overdose).,Common side effects: constipation, nausea, dizziness, drowsiness; increase fluids and fiber to prevent constipation.,Seek emergency help if you experience trouble breathing, chest pain, severe dizziness, black/tarry stools, or signs of allergic reaction.,Keep out of reach of children and dispose of unused medication via drug take-back program.,Inform all healthcare providers that you are taking this medication before any surgery or procedure.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCODONE HYDROCHLORIDE AND IBUPROFEN vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE, answered by our medical review team.
OXYCODONE HYDROCHLORIDE AND IBUPROFEN is a Opioid Agonist that works by Oxycodone is a full mu-opioid receptor agonist, leading to analgesia, euphoria, and sedation. Ibuprofen inhibits cyclooxygenase (COX)-1 and COX-2, reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCODONE HYDROCHLORIDE AND IBUPROFEN and ACETAMINOPHEN AND HYDROCODONE BITARTRATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCODONE HYDROCHLORIDE AND IBUPROFEN is: One tablet containing oxycodone hydrochloride 5 mg and ibuprofen 400 mg orally every 6 hours as needed for pain; maximum 4 tablets per day.. The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCODONE HYDROCHLORIDE AND IBUPROFEN and ACETAMINOPHEN AND HYDROCODONE BITARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCODONE HYDROCHLORIDE AND IBUPROFEN is classified as Category D/X. First trimester: Limited data; opioid use associated with neural tube defects and congenital heart defects in some studies; ibuprofen associated with increased risk of cardiac defe. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.